EGFR and non-small cell lung carcinoma: Further study will be needed for EGFR mutant NSCLC patients with initially brain metastasis who received the third generation TKIs as the first line treatment to investigate the clinical outcomes according to the use of upfront RT as well as the salvage RT following intracranial progression.